Moxetumomab pasudotox Brand Name– LUMOXITI
What is Moxetumomab pasudotox
Moxetumomab pasudotox is a CD22-directed antibody-drug conjugate indicated for the treatment of adult patients with relapsed or refractory hairy cell leukemia who received at least 2 prior systemic therapies, including treatment with a purine nucleoside analog.
Severe cases of capillary leak syndrome and hemolytic-uremic syndrome have been reported with moxetumomab pasudotox use.
Indications
- hairy-cell leukemia
For the treatment of hairy-cell leukemia
NOTE: Moxetumomab pasudotox has been designated by the FDA as an orphan drug for the treatment of hairy-cell leukemia.
for the treatment of relapsed or refractory hairy-cell leukemia in patients who have received at least 2 prior systemic therapies, including treatment with a purine nucleoside analog
Side Effects
- anemia
- anemia
- antibody formation
- ascites
- blurred vision
- capillary leak syndrome
- cataracts
- chills
- conjunctivitis
- constipation
- cough
- diarrhea
- dizziness
- dyspnea
- edema
- elevated hepatic enzymes
- elevated hepatic enzymes
- fatigue
- fever
- fever
- fluid retention
- fluid retention
- flushing
- headache
- hemolysis
- hemolytic anemia
- hemolytic-uremic syndrome
- hemolytic-uremic syndrome
- hyperbilirubinemia
- hyperbilirubinemia
- hyperuricemia
- hyperuricemia
- hypoalbuminemia
- hypoalbuminemia
- hypocalcemia
- hypokalemia
- hypokalemia
- hypomagnesemia
- hypomagnesemia
- hyponatremia
- hyponatremia
- hypophosphatemia
- hypophosphatemia
- hypotension
- infusion-related reactions
- infusion-related reactions
- leukocytosis
- myalgia
- nausea
- nausea
- nephrotoxicity
- neutropenia
- neutropenia
- ocular discharge
- ocular hemorrhage
- ocular pain
- pericardial effusion
- peripheral edema
- pleural effusion
- proteinuria
- pulmonary edema
- renal failure (unspecified)
- sinus tachycardia
- thrombocytopenia
- thrombocytopenia
- thrombocytosis
- thrombosis
- weight gain
- wheezing
- xerophthalmia
Monitoring Parameters
- blood pressure
- CBC with differential
- LDH
- LFTs
- pregnancy testing
- serum albumin
- serum creatinine/BUN
- serum electrolytes
- weight
Contraindications
- breast-feeding
- capillary leak syndrome
- contraception requirements
- electrolyte imbalance
- geriatric
- hemolytic-uremic syndrome
- infusion-related reactions
- pregnancy
- pregnancy testing
- renal impairment
- reproductive risk
- thrombotic microangiopathy
Interactions
- Palifermin
- Penicillamine
- Tuberculin Purified Protein Derivative, PPD
Palifermin: (Moderate) Palifermin should not be administered within 24 hours before, during infusion of, or within 24 hours after administration of antineoplastic agents.
Penicillamine: (Major) Do not use penicillamine with antineoplastic agents due to the increased risk of developing severe hematologic and renal toxicity.
Tuberculin Purified Protein Derivative, PPD: (Moderate) Immunosuppressives may decrease the immunological response to tuberculin purified protein derivative, PPD. This suppressed reactivity can persist for up to 6 weeks after treatment discontinuation. Consider deferring the skin test until completion of the immunosuppressive therapy.
